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Background: Although Methotrexate (MTX) is one of the most commonly prescribed disease-modifying drugs in
JIA no questionnaire exists that assesses the knowledge of parents about this drug. A 60-item questionnaire was
recently developed to measure rheumatoid arthritis (RA) patients’ knowledge about MTX; the Methotrexate in
Rheumatoid Arthritis Knowledge Test (MiRAK; Ciciriello et al. (Arthritis Rheum 62:10–1009, 2010)). This study aimed
to adapt the MiRAK for parents of children with JIA.
Methods: Adaption of the MiRAK involved: 1) email consultations with clinicians working in the field of paediatric
rheumatology (Panel 1) to ascertain the potential adaptations of the MiRAK from a clinical perspective, 2) synthesis
of clinicians’ suggestions by a panel of experts, researchers and MiRAK developers (Panel 2) to reach consensus on
which items needed to be modified and create a draft Methotrexate in Juvenile Idiopathic Arthritis Knowledge Test
(MiJIAK), 3) a review of the draft by 5 parents of children with JIA (Panel 3) using the cognitive ‘think-aloud’
method, 4) a second consultation with Panel 2 to review parents’ suggestions and determine the final items.
Results: A total of 9 items remained unchanged, e.g. “Methotrexate is effective at relieving joint stiffness”, 19 were
deemed inappropriate in the paediatric setting and deleted, e.g. “It is safe to become pregnant 3 weeks after
methotrexate has been stopped”, 32 underwent editorial changes largely to indicate that the questionnaire was
about the children with JIA, e.g. “If you forget to give a dose of Methotrexate, you can still take it the next day”
became “If your child misses a dose of Methotrexate, they can still take it the next day”, and 1 new item was added.
A new 42-item questionnaire was produced and was found to be well understood by parents of children with JIA.
Conclusions: The systematic modification of the MiRAK, a patient-centred MTX knowledge questionnaire, has
generated a comprehensive new questionnaire for use in the JIA setting. The wide consultation process, including
cognitive testing, has ensured the tool is both relevant and acceptable to clinicians and will therefore be a valuable
addition in understanding the parents’ perspective of this treatment in JIA.
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Juvenile idiopathic arthritis (JIA) is the most common
rheumatic inflammatory disorder found in children, with
an annual incidence of approximately 10 per 100,000
children [1]. The International League of Associations
for Rheumatology (ILAR) criteria define JIA as occurring
in children under the age of 16 years where arthritis in
one or more joints persists for more than 6 weeks with
unknown cause [2]. As there is currently no cure, med-
ical intervention aims to manage the illness and its
symptoms, principally pain, stiffness and joint swelling
[3]. Methotrexate (MTX) is the most commonly used
disease modifying drug (DMARD) in JIA and has been
widely shown to generate considerable improvement
in symptoms [3]. However, MTX is not effective for all
children [4].
Parents play an important role in the management of
their child’s illness and there are few chronic diseases as
challenging for a child and their parents as severe JIA
[5]. One major issue that concerns parents is the pos-
sible side effects of their child’s medication [6]. MTX is
known to cause a number of unpleasant side effects,
including nausea, vomiting, diarrhoea and mouth sores,
and these can be distressing for both the child and par-
ent [7] MTX is also used to treat cancer. This requires
much higher doses and carries the risk of greater toxicity
than low-dose MTX used for JIA. Parents may be
alarmed by information about MTX that is not specific
to JIA and lists side effects that do not occur with low-
dose MTX treatment. Given the potential difficulties
around the use of MTX for treating JIA, and the role
parents play in supporting the management of the dis-
ease, it is important that parents receive accurate infor-
mation from clinicians about MTX. Assessment of
parents’ knowledge regarding medications in JIA reveals
that this may be quite limited and consequently, educa-
tional interventions able to increase knowledge signifi-
cantly are necessary [8].
It is important to have measures specifically designed
for parents to capture the unique experiences of caring
for a child with a chronic illness, and the knowledge
they have about their child’s treatment. Questionnaires
can provide a valid and reliable way to evaluate the ef-
fectiveness of education efforts [9] and can assist
healthcare providers in determining how best to use re-
sources such as staff time when developing education
packages and assisting parents. However, there is no
comprehensive, validated and reliable measure of MTX
knowledge in parents of children with JIA. To date stud-
ies have used methods with limited reproducibility and
validity [8] including unstructured observations and
investigator-designed questions.
This study therefore aimed to adapt a robust measure
of MTX knowledge for adult rheumatoid arthritispatients for use with parents of children with JIA.
The Methotrexate in Rheumatoid Arthritis Knowledge
(MiRAK) questionnaire was developed using grounded
approaches involving both clinicians working in the field
of rheumatology and patients with RA [10]. The ques-
tionnaire consists of 60 items that were based on the
words and concepts used by people with the condition,
clinical relevance, and the published literature. Respon-
dents answer each statement as either ‘true’, ‘false’ or
‘don’t know’. Scores are calculated by adding together
the number of correct responses. The MiRAK has been
reported to have excellent psychometric properties in-
cluding good model fit, supporting internal construct
validity; good internal consistency (person separation
index 0.84); test-retest reliability (ICC 0.89) and ability
to detect change (Effect Size 2.38) [10].Methods
Study design
This study adapted the MiRAK for use by parents of
children with JIA using the Delphi technique, expert
consensus, followed by cognitive think-aloud interviews
with parents of children with JIA.The Delphi technique
We used the Delphi technique [11] to obtain feedback
regarding which items to include in the revised tool.
This process involved 3 panels of experts; a group of
paediatric rheumatologists, a panel of researchers work-
ing in rheumatology and parents of the children with
JIA. The Delphi method has been previously used in
health services research [12,13], including the context of
questionnaire construction and validation alongside the
use of think aloud interviews [14].Think-aloud technique
The think-aloud technique involves asking a respondent
to comment on a task while undertaking the task, thus
providing rich verbal data on the experience of complet-
ing a tool. Think-aloud interviewing is an established
method used in the adaptation and validation of ques-
tionnaires in health settings [15,16]. In the present study
two interviewers instructed each parent to provide a
running commentary on their thoughts about each ques-
tionnaire item using an interview schedule. Some prob-
ing questions such as “what are your feelings about that
item?” were used to encourage parents to continue to
think aloud, whilst contributions made by the inter-
viewer during this process were kept to a minimum. Par-
ents were also asked to make any suggestions for
additional items they felt should be included.
Wickwar et al. Pediatric Rheumatology 2013, 11:27 Page 3 of 6
http://www.ped-rheum.com/content/11/1/27Participants
A convenience sample of 3 paediatric rheumatologists
and one rheumatology nurse specialist was recruited to
Panel 1. This type of sampling involves approaching only
those available during the recruitment period. A second
panel consisted of two authors of the MiRAK (a
rheumatologist and a professor of public health), a pro-
fessor in paediatric rheumatology, a professor in health
psychology and 2 research assistants working in JIA. The
third panel consisted of parents and was recruited via
one centre (Great Ormond Street Hospital). Parents
were invited to participate if they; [1] were either the
mother or father of a child with JIA, [2] had experience
of giving their child MTX, [2] were already taking part
in the Childhood Arthritis Response to Medication
Study (CHARMS), [3] had clinic appointments booked
during the recruitment period for this study and [4]
were able to understand and speak English. A total of 36
parents were identified as being eligible and were invited
to take part in the study, of these 5 agreed to participate.
Participating parents were also asked to complete a
demographics questionnaire that recorded their age, em-
ployment status, level of education, their child’s JIA sub-
type, and the length of time since their child’s diagnosis.
Members of Panel 3 were aged between 35 and 50 years.
Two were full-time homemakers, two were full-time
employed, and one did not disclose their occupation. All
of the parents were married or lived with their partner,
and all lived with their child who had JIA. The majority
were educated to degree level with two parents educated
to postgraduate level. The children of these parents ei-
ther had extended oligoarthritis, polyarticular JIA or
psoriatic JIA. All children were still taking MTX at the
time of the study and had been living with the diagnosis
of JIA for between 3 and 9 years.
Data collection and analysis
Quantitative data were recorded at each of the following
stages using descriptive statistics. Frequencies were used
to examine the number of times suggestions were made
about the retention, removal or adaptation of an item by
both the paediatric rheumatologists and parents.
Stage 1
Members of Panel 1 were sent a pre-designed question-
naire adaptation form that consisted of instructions for
clinicians and a list of all the original MiRAK items.
There was space for clinicians to make suggestions for
editing each item and the document automatically
tracked the changes that they made. Members of Panel 1
were instructed to review each item of the MiRAK and
recommend whether each item should “stay as it is”, “be
deleted”, or “be reworded”. Respondents were also in-
vited to suggest rewording. Responses were then codedby 2 researchers into one of the following groups “modi-
fication of original MiRAK item”, “deletion of original
MiRAK item”, or “original MiRAK item retained”. Re-
sponses from all 4 members were then consolidated.
Stage 2
Results were presented to Panel 2 containing the re-
sponses from Panel 1 on each individual item. Consider-
ing these results Panel 2 then made decisions on the
consistency of the responses across the 4 participants,
the consistency of the wording between items, the rele-
vance of the item to JIA and the accuracy of the content
of each item. Initially, any items for which there was
100% agreement between the clinicians were retained.
The remaining items were put forward for discussion by
the members of Panel 2. The development of new items
was based on the general rules and principles of item
construction used in previous questionnaire develop-
ment research [17]. Consensus was reached through dis-
cussion until a first version of the new questionnaire was
agreed upon.
Stage 3
Following consent this draft questionnaire was then
presented to parents of children with JIA within cogni-
tive think-aloud interviews. These interviews lasted ap-
proximately one hour and each was recorded. Interviews
with parents were transcribed and coded using the codes
from stage 1 i.e. “modification of item”, “deletion of
item”, “item retained”, or “addition of new item”. Where
parents made comments about the acceptability of an
item, these were coded either “clear”, “acceptable” or
“difficult to understand”.
Stage 4
The input provided by the parents was then assessed by
Panel 2 to create the final version of the questionnaire.
If there was not 100% agreement between the parents in
terms of retaining or adapting an item, the two research
assistant members of the panel made suggestions about
possible alternatives which were reviewed and agreed by
the remaining members of the panel.
Ethical approval
The study received approval from the GOSH Research
Ethics Committee.
Results and discussion
Figure 1 summarizes the results obtained from each
stage of the Delphi process.
Stage 1: panel 1 item review
All 4 members of Panel 1 agreed that one of the MiRAK
items needed to be removed from the questionnaire, as
10
Panel 1 review original 
MiRAK (item n=60)
First adaptation of 
MiRAK by Panel 2, 
consensus achieved 
(item n=46)





Second adaptation of 




version 2   
(item n=42)
Figure 1 Results from each stage of the Delphi process.
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(one tablet or less a day) should not be taken while on
methotrexate” - False). Panel 1 also agreed on 11 items
that needed to be reworded to make them relevant to
JIA; the predominant change was minor (e.g. “rheuma-
toid arthritis” to “juvenile idiopathic arthritis”). There
was consistent advice for 9 items to be retained as in the
original questionnaire. The remaining items (n= 39) for
which 100% agreement was not reached amongst the cli-
nicians were reviewed by Panel 2.
Stage 2: panel 2 consensus & MiJIAK first draft
Panel 2 removed an item originally retained by Panel 1
as it was not considered to have adequate evidence to
provide a clear true/false response in JIA (“Methotrexate
can reverse joint damage caused by rheumatoid arthritis” -
False). Of the 39 items where Panel 1 did not reach con-
sensus, 12 items were removed as they were found to be
not relevant in JIA; a further 4 were retained as in the ori-
ginal questionnaire and the remaining items (n=23) were
adapted by Panel 2 often with small amendments. (e.g.
“You should keep taking methotrexate even when your
joints are not painful” was changed to “Your child should
keep taking methotrexate even when their joints are not
painful”). As a result of this second process the original
60-item MiRAK was adapted to create the first draft of a
46-item Methotrexate in Juvenile Idiopathic Arthritis
Knowledge (MiJIAK) questionnaire.
Stage 3: parents’ think aloud interviews
Of the 46 items all parents agreed that 23 items were
clear and acceptable. Parents queried the clarity of thewording of 4 items and the relevance of two items. For
example, one parent said "That I'd find quite worrying…
people may think the liver's going to go wrong" in regards
to the item “Scarring of the liver is a common side effect
of methotrexate” - False. Parents also suggested 1 add-
itional item to be included, “There's nothing in there
about the best time to take MTX, and about food that
should or shouldn't be eaten”. As a result a new item was
added “Methotrexate should be taken on the same day
each week” - True.
Stage 4: panel 2 consensus & final version of MiJIAK
A second consultation took place with Panel 2 to review
parents’ suggestions and to reach consensus on the in-
clusion and wording of the final items. Concerns
expressed by parents on the item regarding scarring of
the liver resulted in it being removed. The medical ac-
curacy of two items for their use in the case of JIA was
further queried by the panel and this resulted in them
being removed because of lack of clear evidence in JIA
(e.g. “Methotrexate does not slow the joint damage
caused by rheumatoid arthritis” - False) Four additional
items were removed from the final version as parents
felt there was either a lack of clarity or the question was
not relevant to children. (e.g. “If you are unable to eat or
drink you should still try to take your methotrexate” –
False)
In total, 9 items remained unchanged, 19 were deleted,
the wording of 32 was changed, and 1 new item was
added. The final version of the MiJIAK questionnaire
has 42 items and includes a variety of ‘true’ and ‘false’
response scores (29 and 13 respectively). The 42-item
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file shows the questionnaire [see Additional file 1].
Readability
To determine the reading level of the questionnaire, the
Flesch-Kincaid Reading Ease and Flesch-Kincaid Grade
Level tests [18] were performed on the final version of
the MiJIAK, including the instructions and each of the
42 items of the questionnaire. A Flesch-Kincaid Reading
Ease score of 49 (higher scores out of 100 indicate easier
readability) and a Flesch-Kincaid Grade Level of 10
(i.e. 15 to 16 years old) were found.
Discussion
The adaption of the MiRAK for use with parents of chil-
dren with JIA was achieved through the use of consulta-
tions with clinicians to identify necessary changes from a
medical perspective and researchers to ensure clarity
and consistency. These consultations were followed by
cognitive think-aloud interviews with parents of children
with JIA to obtain opinions from the target population
about the clarity and acceptability of the new question-
naire. This resulted in the new 42-item Methotrexate in
Juvenile Idiopathic Arthritis Knowledge Test (MiJIAK),
which parents found clear to understand and was ac-
ceptable to clinicians in the field.
This is the first questionnaire designed to measure
MTX knowledge specifically in parents of children with
JIA. Such a questionnaire can be used in the context of
JIA to highlight the educational needs of an individual
or population to ensure knowledge from the parent’s
perspective. Ensuring that parents have good knowledge
lays the foundation for appropriate administration of
medication and potentially reduces anxiety around MTX
and its administration. The questionnaire can also be
used to evaluate the effectiveness of educational inter-
ventions undertaken with parents responsible for admin-
istering their child’s MTX.
The think-aloud interviews permit the gathering of crit-
ical data about how to adapt the MiRAK using the imme-
diate and honest thoughts of parents. Involving the target
group in this way generated insight into the appro-
priateness of the MiJIAK for use with parents and ensured
that the questionnaire had good content validity.
The Delphi method used offered a rigorous process by
which to distribute and process data and to reach con-
sensus about which items to include in the revised ques-
tionnaire and how best to word them. This method also
allowed discussions to take place between members of
the panel that could not be present physically, such as
those based in Australia.
There are however some limitations in the study’s de-
sign. Firstly, the think-aloud interviews generated varying
amounts of data from parents. The technique as describedby Willis 1999; [19] involves a process of participants en-
gaging with the research by providing a running commen-
tary of their thoughts about a particular topic, which
assumes participants are highly cognitively able and can
be successfully engaged. The abilities of some of the par-
ents may not have met these requirements, thus generat-
ing data that differed in both quantity and quality.
Secondly, any conclusions that were made about
adapting specific questionnaire items were based on the
suggestions of a small sample of mostly well educated
middle aged adults, which may not have been represen-
tative of the population. A larger, more diverse sample
may have been more appropriate. The questionnaire was
found to be suitable for the reading level of 15 to 16 year
olds, which may be limiting for some respondents.
Thirdly, this adaptation study does not include the val-
idation and field testing of the revised questionnaire.
Further testing in a variety of settings will provide add-
itional data on the validity and reliability of the question-
naire and thus generate data regarding the utility of the
tool [20]. Given the rigorous development of the tool,
including a strong reliance on the most recent published
literature and input from experienced rheumatologists
from both the UK and Australia, the tool has very good
face and content validity and is likely to reveal important
information about the accuracy of the knowledge of par-
ents of children with JIA.
Conclusions
The 42-item MiJIAK is the first MTX knowledge ques-
tionnaire designed specifically for parents of children
with JIA and can be used to generate insight into the in-
formation needs, the quality of information provided to
parents, and the outcome of education interventions in
this field. Prior to this however, further research to ex-
plore the validity and reliability of the revised measure
across settings will facilitate the MiJIAK’s application
into the research and clinical setting.
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